S

Shanghai Henlius Biotech Inc
HKEX:2696

Watchlist Manager
Shanghai Henlius Biotech Inc
HKEX:2696
Watchlist
Price: 62.55 HKD 3.3% Market Closed
Market Cap: 34B HKD

Operating Margin
Shanghai Henlius Biotech Inc

16.1%
Current
1%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
16.1%
=
Operating Profit
931m
/
Revenue
5.8B

Operating Margin Across Competitors

No Stocks Found

Shanghai Henlius Biotech Inc
Glance View

Market Cap
34B HKD
Industry
Biotechnology

In the heart of China's bustling financial district, Shanghai Henlius Biotech Inc. stands proud as a beacon of innovation in the biopharmaceutical industry. Founded in 2010, Henlius has rapidly grown to become a notable player in the development of monoclonal antibodies, with a focus on oncology, autoimmune disorders, and ophthalmic conditions. The company's business model is rooted in its robust research and development capabilities, which are supported by strategic partnerships and a dedicated pipeline. By harnessing state-of-the-art technology and a global talent pool, Henlius crafts biosimilar and innovative biological drugs designed to meet the escalating health needs across the globe. With a strong focus on cutting-edge R&D, they have successfully commercialized several key products that have gained regulatory approval, allowing them to penetrate both domestic and international markets. Revenue flows into Henlius through a diversified portfolio that stretches beyond drug development to encompass manufacturing and sales partnerships. By leveraging their fully-integrated biopharmaceutical platform, Henlius not only develops its proprietary medications but also collaborates with other pharmaceutical giants to bring products to market efficiently. These collaborations often translate into licensing agreements and royalties, which provide Henlius with recurring income streams. The company's ability to navigate complex regulatory environments and its strategic expansion into global markets – including Europe, Southeast Asia, and Latin America – further reinforces its revenue-generating capacity. Thus, Henlius stands as a testament to the power of strategic ingenuity and cutting-edge science in the ever-evolving landscape of global healthcare.

Intrinsic Value
27.78 HKD
Overvaluation 56%
Intrinsic Value
Price
S
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
16.1%
=
Operating Profit
931m
/
Revenue
5.8B
What is the Operating Margin of Shanghai Henlius Biotech Inc?

Based on Shanghai Henlius Biotech Inc's most recent financial statements, the company has Operating Margin of 16.1%.

Back to Top